These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

727 related items for PubMed ID: 23675525

  • 21. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S.
    Circulation; 2014 Jul 29; 130(5):431-41. PubMed ID: 25070550
    [Abstract] [Full Text] [Related]

  • 22. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD, Lee SE, Yang J, Lee HC, Shin D, Lee H, Lee J, Jin S, Kim S, Lee SJ, You J, Park HW, Nam KY, Lee SH, Park SW, Kim JS, Kim SY, Kwon YW, Kwak SH, Yang HM, Kim HS.
    Eur Heart J; 2020 Jan 07; 41(2):239-252. PubMed ID: 31419281
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
    Tai MH, Chen PK, Chen PY, Wu MJ, Ho CT, Yen JH.
    Mol Nutr Food Res; 2014 Nov 07; 58(11):2133-45. PubMed ID: 25164566
    [Abstract] [Full Text] [Related]

  • 25. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.
    Lagace TA.
    Curr Opin Lipidol; 2014 Oct 07; 25(5):387-93. PubMed ID: 25110901
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.
    Saavedra YG, Day R, Seidah NG.
    J Biol Chem; 2012 Dec 21; 287(52):43492-501. PubMed ID: 23105118
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M, Terao Y, Ayaori M, Uto-Kondo H, Iizuka M, Yogo M, Hagisawa K, Takiguchi S, Yakushiji E, Nakaya K, Ogura M, Komatsu T, Ikewaki K.
    Arterioscler Thromb Vasc Biol; 2014 Jun 21; 34(6):1171-8. PubMed ID: 24675665
    [Abstract] [Full Text] [Related]

  • 34. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.
    Hepatology; 2008 Aug 21; 48(2):646-54. PubMed ID: 18666258
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.
    Miranda MX, van Tits LJ, Lohmann C, Arsiwala T, Winnik S, Tailleux A, Stein S, Gomes AP, Suri V, Ellis JL, Lutz TA, Hottiger MO, Sinclair DA, Auwerx J, Schoonjans K, Staels B, Lüscher TF, Matter CM.
    Eur Heart J; 2015 Jan 01; 36(1):51-9. PubMed ID: 24603306
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.
    Holla ØL, Strøm TB, Cameron J, Berge KE, Leren TP.
    Mol Genet Metab; 2010 Feb 01; 99(2):149-56. PubMed ID: 19828345
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation.
    Seidah NG, Poirier S, Denis M, Parker R, Miao B, Mapelli C, Prat A, Wassef H, Davignon J, Hajjar KA, Mayer G.
    PLoS One; 2012 Feb 01; 7(7):e41865. PubMed ID: 22848640
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.